Grand Pharmaceutical Group Limited (HKG:0512)
Hong Kong
· Delayed Price · Currency is HKD 8.16
-0.05 (-0.61%)
At close: Dec 5, 2025
HKG:0512 Revenue
Grand Pharmaceutical Group had revenue of 6.11B HKD in the half year ending June 30, 2025, with 1.97% growth. This brings the company's revenue in the last twelve months to 11.70B, up 10.56% year-over-year. In the year 2024, Grand Pharmaceutical Group had annual revenue of 11.64B with 10.59% growth.
Revenue (ttm)
11.70B
Revenue Growth
+10.56%
P/S Ratio
2.44
Revenue / Employee
940.91K
Employees
11,987
Market Cap
28.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.64B | 1.12B | 10.59% |
| Dec 31, 2023 | 10.53B | 967.31M | 10.12% |
| Dec 31, 2022 | 9.56B | 964.31M | 11.22% |
| Dec 31, 2021 | 8.60B | 2.25B | 35.34% |
| Dec 31, 2020 | 6.35B | -237.72M | -3.61% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 38.69B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |